A number of medical companies submit their forms again after the IPO "failed"

 In recent years, there has been a boom in the listing of medical companies in Hong Kong
.
According to statistics, as of December 17, 2021, there were 54 new economy companies, accounting for 86.
6% of the IPO funds raised in Hong Kong during the period
.
Of the 54 companies, 32 are healthcare and biotech companies
.
Recently, many medical companies have failed to submit their IPOs again
.
Among them, from February 14th to 21st, 3 medical companies were listed due to the expiration of the prospectus
.
The three companies include Inference Medical, Main Gene, and Northchip Life
.
Inference Medical On February 21, 2022, the listing application materials of AI medical company Inference Medical Technology Co.
, Ltd.
(referred to as "Inference Medical") have been "invalid"
.
This means that Inference Medical's first sprint for listing on the Hong Kong Stock Exchange failed
.
However, Inferred Medical received approval from the China Securities Regulatory Commission in November 2021: Inferred Medical was approved to issue no more than 22,422,300 overseas listed foreign shares, with a par value of RMB 1 per share, all of which are ordinary shares
.
After the completion of this issuance, the company can be listed on the main board of the Hong Kong Stock Exchange (ie the Hong Kong Stock Exchange), which also means that it is expected that the medical treatment will be submitted on the Hong Kong Stock Exchange again in the near future
.
According to the data, in 2020, the operating income of Inferred Medical will increase by 318% year-on-year to 27.
7 million yuan, and in the first quarter of 2021, the revenue will increase by 357% year-on-year to 22.
13 million yuan
.
However, in terms of profits, it is estimated that in the first quarter of 2019, 2020 and 2021, the adjusted net profit and loss of medical treatment were 152 million yuan, 125 million yuan and 126.
95 million yuan
.
The industry said that although Inferential Medical is not yet profitable, it is still favored by capital
.
In addition, according to the data, as of March 31, 2021, Intuition Medical’s cash and cash equivalents were 272 million yuan.
In July 2021, Inferential Medical had completed the D2 round of financing, and the total amount of the D round of financing was nearly 900 million yuan
.
Main Gene On February 16, 2022, the genetic testing platform company - Main Gene's prospectus expired
.
It is reported that Main Gene went to Hong Kong to submit the application on August 16 last year, but the application status became invalid because the hearing was not passed within six months
.
However, the day after the prospectus expired, Maingene quickly updated the prospectus information and started its second listing in Hong Kong
.
According to the disclosure of the Hong Kong Stock Exchange on February 17, Main Gene submitted a listing application to the main board of the Hong Kong Stock Exchange, and China Securities Investment International was the sole sponsor
.
According to the prospectus, as of September 30, 2021, Maingene has performed more than 11 million genetic tests; based on the revenue generated in 2020, Maingene's market share is 34.
2%
.
From the performance point of view, from 2018 to 2020 and the first three quarters of 2021, MainGene achieved operating income of 195 million yuan, 124 million yuan, 203 million yuan and 152 million yuan respectively; the net profit was 22 million yuan, 29.
7 million yuan, 79.
1 million yuan and 41.
6 million yuan
.
Northchip Life Recently, the listing application materials of Shenzhen Northchip Life Science and Technology Co.
, Ltd.
(“Northchip Life”) have expired and cannot be viewed or downloaded normally
.
This means that North Core's first sprint to be listed on the Hong Kong Stock Exchange has already failed
.
It is reported that before the IPO of Northchip Life, a total of 6 rounds of financing have been completed.
The investors include Sequoia China, Decheng Capital, SDIC Chuanghe, Qiming Venture Capital, Boyu Capital, Tigermed and other institutions
.
Among them, in June 2021, Northchip conducted a $85 million Series D financing
.
After the completion of the D round of financing, the post-transaction valuation of Northchip reached 5.
043 billion yuan
.
However, from the performance point of view, in the first quarter of 2019, 2020 and 2021, Beixin Life achieved operating income of 0 yuan, 1.
588 million yuan, and 4.
753 million yuan respectively, and the corresponding net profits were -39.
644 million yuan and -57.
115 million yuan respectively.
, -25.
836 million yuan
.
Analysts said that medical companies have strong uncertainty in future development due to high research and development costs.
In order to better promote the company's development, they need strong capital support, and Hong Kong stocks are listed quickly, so medical companies choose to list in Hong Kong. .
It is reported that in addition to companies such as Intuition Medical and Main Genetics, many companies such as Bioer Technology, Jianshi Technology, Yida Health, and Ruike Biotech also chose to submit the prospectus to the Hong Kong Stock Exchange for the second time due to the expiration of the prospectus.
book
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.